Definer DF2000 Knife Mill from Franklin Miller Offers Ease of Use
The device focuses on ease of maintenance and reliability while cutting materials to desired output size without overgrinding or excessive heat build-up.
The Definer DF2000 knife mill from Franklin Miller focuses on ease of maintenance and reliability while cutting materials to desired output size without overgrinding or excessive heat build-up. The company introduced the product on Nov. 14, 2019.
The device’s rotor design comes equipped with replaceable rotary knife elements and several cutter elements and screen sizes that allow for the customization of the condition, mill, and deagglomerate of the device. The stainless-steel hopper and protective flaps help to keep work environments clean, while the rotational speed, particle size, and throughput are maintained with the knife mill’s variable speed controller. Additional add-ons are also available and include casters with lockable wheels and a pneumatic discharge system.
Source: Franklin Miller
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Large-Scale LNP Process Conversions: The many hurdles of LNP scale-up and what to consider
May 12th 2025Lipid nanoparticle (LNP) formulation development begins on a small scale, often with homemade or benchtop setups, using syringe pumps and easily accessible micro-mixing systems. Once a promising formulation has been identified, the next step is to transition to standardized large-scale impingement mixing systems, such as the high flow T-mixing pumps that were used to produce the COVID-19 vaccines (Sealy 2021). Formulators need to consider a number of factors when scaling up novel LNP systems. These include flow rates that affect LNP particles, solvent removal, risk factors when changing equipment, and the impact of tangential flow filtration sensitivity. In this technical note, we discuss these factors and what needs to be considered when developing a cost- and time efficient large-scale process.
